Please enable JS

Investors & Media

2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
Dec-21-2015Bayer and CRISPR Therapeutics AG join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases
The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technologyBayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unitThe joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well as protein engineering and disease know-how by BayerLeverkusen, Germany and Basel, Switzerland, December 21, 2015 – ... 
Printer Friendly Version
Dec-18-2015Généthon and CRISPR Therapeutics announce Research Collaboration
EVRY, France, BASEL, Switzerland and CAMBRIDGE, Mass. – December 16th, 2015 – Généthon, a leader in the field of gene therapy treatments for rare diseases, and CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, have today announced an ongoing research collaboration. Généthon is supporting the development of one CRISPR Therapeutics' undisclosed propriety programs. Généthon's expertise is in the pre-clinica... 
Printer Friendly Version
Dec-11-2015CRISPR Therapeutics Appoints Tony Coles, M.D., to its Board of Directors
BASEL, Switzerland – December 11, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Tony Coles, M.D., to the company's Board of Directors."Dr. Coles is a venerated leader in the biotech industry with a strong track record of success," said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics. "The appointment of Dr. Coles is in line with our effort ... 
Printer Friendly Version
Oct-26-2015Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases
–Gene editing technology to be used to discover treatments to address the mutations and genes known to cause and contribute to cystic fibrosis- -Vertex and CRISPR to utilize gene editing approach to discover treatments for genetic diseases, including sickle cell disease- -Companies establish four-year research collaboration; CRISPR to receive $105 million up-front payment, of which $30 million is an equity investment and $75 million is cash, with potenti... 
Printer Friendly Version
Sep-30-2015FierceBiotech names CRISPR Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
BASEL, Switzerland and CAMBRIDGE, Massachusetts – Spetember 30, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced that it has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. "It is an absolute honor to be recognized by FierceBiotech as o... 
Printer Friendly Version
Aug-11-2015CRISPR Therapeutics Bolsters Management Team with Samarth Kulkarni as Chief Business Officer and Michael Bruce as Senior Vice President, Program Portfolio and Alliance Management
BASEL, Switzerland and CAMBRIDGE, Massachusetts – August 11, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into cures for serious human diseases, today announced the expansion of the leadership team with the appointments of Samarth Kulkarni, Ph.D., as Chief Business Officer and Michael Bruce, Ph.D., as Senior Vice President, Program Portfolio and Alliance Management. “Dr. Kulkarni and Dr. Bruce both b... 
Printer Friendly Version
Apr-29-2015CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients
BASEL, Switzerland and CAMBRIDGE, Massachusetts – April 29, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced the closing of a Series A and Series B financing totaling USD 89 million, including USD 35 million of new funding in the Series A and USD 29 million in the Series B. The oversubscribed Series A and Series B financings were led by strategic investors, SR One and Celgene Corporat... 
Printer Friendly Version
Apr-22-2015CRISPR Therapeutics Congratulates Scientific Founder Dr. Emmanuelle Charpentier on Addition to TIME Magazine’s 100 Most Influential People and Award of Louis Jeantet Prize for Medicine
BASEL, Switzerland and CAMBRIDGE, Massachusetts – April 22, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, congratulates its scientific founder, Dr. Emmanuelle Charpentier, for being named to TIME Magazine’s TIME 100 Most Influential People in the World alongside fellow CRISPR-Cas9 discoverer, Dr. Jennifer Doudna. In addition, Dr. Emmanuelle was awarded the Louis Je... 
Printer Friendly Version
Apr-07-2015CRISPR Therapeutics to Establish R&D Operations in Cambridge, Massachusetts
–Company Appoints Bill Lundberg, M.D., as Chief Scientific Officer– BASEL, Switzerland and CAMBRIDGE, Massachusetts – April 7, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines for serious human diseases, today announced the appointment of Bill Lundberg, M.D., to Chief Scientific Officer to lead the Company’s development programs and to spearhead the creation of its R&D o... 
Printer Friendly Version
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet